Dimensional Fund Advisors LP Purchases 91,679 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Dimensional Fund Advisors LP raised its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 38.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 330,181 shares of the biopharmaceutical company’s stock after acquiring an additional 91,679 shares during the period. Dimensional Fund Advisors LP owned about 0.68% of Theravance Biopharma worth $2,800,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in TBPH. Gerber LLC purchased a new stake in Theravance Biopharma during the 4th quarter valued at about $112,000. Wellington Management Group LLP boosted its holdings in Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock valued at $3,227,000 after acquiring an additional 116,164 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Theravance Biopharma by 16.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock worth $474,000 after purchasing an additional 7,509 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 3,532 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its stake in Theravance Biopharma by 28.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 4,990 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Insider Activity

In other Theravance Biopharma news, major shareholder Eli Samaha bought 999,800 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was acquired at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the transaction, the insider now directly owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $8.06 on Friday. The company has a market cap of $394.30 million, a PE ratio of -9.37 and a beta of 0.25. The firm’s 50-day moving average price is $8.20 and its 200-day moving average price is $8.80. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The business had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. During the same quarter in the prior year, the business posted ($0.28) EPS. As a group, equities research analysts anticipate that Theravance Biopharma, Inc. will post -1.04 EPS for the current fiscal year.

Analysts Set New Price Targets

TBPH has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. Finally, TD Cowen reduced their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.